The Online Investor
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Diagnostics M&A image Diagnostics M&A » By The Online Investor Staff, updated Sun., Apr. 28, 10:01 AM Recent mergers and acquisitions in the Diagnostics M&A category.

Slide #27. Quest Diagnostics Solstas Lab Partners

Acquirer: Quest Diagnostics (NYSE:DGX)
Acquiree: Solstas Lab Partners
Details: Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has entered into a definitive agreement under which Quest will acquire Solstas Lab Partners Group and its subsidiaries (Solstas) for a total transaction value of approximately $570 million. Solstas is a portfolio company of Welsh, Carson, Anderson and Stowe, a private-equity firm specializing in information/business services and healthcare businesses.

Quest Diagnostics provides diagnostic information services. Co. is made up of two businesses: Diagnostic Information Services, which develops and delivers diagnostic information services, providing insights that allow and enable a range of customers, including patients, clinicians, hospitals, independent delivery networks (including hospital health systems), health plans, employers, accountable care organizations and direct contract entities; and Diagnostic Solutions, which includes Co.'s risk assessment services business, which provides solutions for insurers, and Co.'s healthcare information technology businesses, which provides solutions for healthcare providers.

Quest Diagnostics SEC Filing Email Alerts Service


Open the DGX Page at The Online Investor »

Company Name:  Quest Diagnostics, Inc.
Stock buyback:  DGX buyback
Website:  www.QuestDiagnostics.com
Sector:  Diagnostics
Number of ETFs Holding DGX:  113
Total Market Value Held by ETFs:  $2.81B
Total Market Capitalization:  $15.23B
% of Market Cap. Held by ETFs:  18.46%
 

Open the DGX Page at The Online Investor (in a new window) »

April 28, 2024    10:01 AM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree DGX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.53 out of 4)
6th percentile
(ranked lower than approx. 94% of all stocks covered)

Analysts' Target Price:
DGX Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Diagnostics M&A - Slide 27 of 100 | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.